Drug Topics November 22, 2023
Increased health care access to devices like the continuous glucose monitor (CGM) could improve health outcomes for underserved patients who may otherwise be hindered from their use.
Use of a continuous glucose monitor (CGM) among medically underserved patients can lead to a significant improvement in glycemic control in those being treated for type 2 diabetes (T2D), regardless of treatment therapies used, according to a new study published in Clinical Therapeutics.1
Although the American Diabetes Association recommends either a blood glucose monitor or a CGM for patients with T2D, it also acknowledges the high costs of these devices might render them unaffordable to both insured and uninsured patients. In conducting the current study, investigators aimed to evaluate the effect of initiating...
Today's Sponsors
Today's Sponsor